Search results
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks· 6 days agoFree Report) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Medical - Biomedical and Genetics industry, which Gilead falls ...
Decoding Gilead Sciences's Options Activity: What's the Big Picture? - Gilead Sciences (NASDAQ:GILD)
Benzinga· 6 days agoLoading... Loading... Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD ...
California Supreme Court Will Review Novel Negligence Theory for Pharmaceutical Manufacturers | JD...
JD Supra· 1 day agoThe Situation: The California Supreme Court recently granted review of a California Court of Appeal decision, Gilead Life Sciences, Inc. v. The Superior Court of the City ...
California Supreme Court to Review Newly Created Duty to Market a “Safer” Product Even in the...
JD Supra· 6 days agoOn May 1, the California Supreme Court granted Gilead Science Inc.’s request to review a California appellate court’s holding that the pharmaceutical manufacturer must defend ...
US FDA approves expanded use of Bristol Myers' cancer cell therapy
Reuters· 11 hours ago, opens new tab cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer...
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
InvestorPlace via Yahoo Finance· 7 days agoBiotech breakthrough stocks, along with the sector overall, faced significant challenges over the...
Jennifer Hudson Receives GLAAD Ally Award, 17 Years After Presenting It to Patti LaBelle
People via Yahoo News· 4 days agoIn the episode, Ian Haddock, HIV activist and founder of The Normal Anomaly Initiative, which...
How to Watch the 2024 GLAAD Media Awards Online
Rolling Stone via Yahoo News· 5 days agoThe 35th Annual GLAAD Media Awards in New York will also be presented this year by Gilead Sciences and Hyundai Motor America, with Official Sponsors...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 3 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Earnings call: Arcus Biosciences Reports Strong Q1 2024 Performance By Investing.com
Investing.com· 7 days agoWith GAAP revenue of $145 million for the first quarter and expectations to recognize $30 million...
